celecoxib has been researched along with Carcinoma, Renal Cell in 6 studies
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cytokine-naive metastatic renal cell carcinoma patients with tumors expressing ≥10% maximal COX-2 staining by immunohistochemistry received IFN-α 5 million units daily and celecoxib 400 mg orally twice daily in an open-label, single-arm phase II trial." | 2.76 | Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. ( Dreicer, R; Elson, P; Finke, JH; Garcia, JA; Ireland, J; Rini, BI; Schwandt, A; Triozzi, P; Wyckhouse, J; Zhou, M, 2011) |
| "The observed median time to disease progression (TTP) for the entire cohort was 3." | 2.72 | Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. ( Bok, R; Dunlap, S; Elchinoff, A; Rini, BI; Simko, J; Small, EJ; Weinberg, V; Yu, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, Q | 1 |
| Guo, J | 1 |
| Wang, G | 1 |
| Chu, Y | 1 |
| Hu, X | 1 |
| Schwandt, A | 1 |
| Garcia, JA | 1 |
| Elson, P | 1 |
| Wyckhouse, J | 1 |
| Finke, JH | 1 |
| Ireland, J | 1 |
| Triozzi, P | 1 |
| Zhou, M | 1 |
| Dreicer, R | 1 |
| Rini, BI | 2 |
| Onishi, T | 1 |
| Suzuki, H | 1 |
| Igarashi, T | 1 |
| Wang, X | 1 |
| Zhang, L | 1 |
| O'Neill, A | 1 |
| Bahamon, B | 1 |
| Alsop, DC | 1 |
| Mier, JW | 1 |
| Goldberg, SN | 1 |
| Signoretti, S | 1 |
| Atkins, MB | 1 |
| Wood, CG | 1 |
| Bhatt, RS | 1 |
| Weinberg, V | 1 |
| Dunlap, S | 1 |
| Elchinoff, A | 1 |
| Yu, N | 1 |
| Bok, R | 1 |
| Simko, J | 1 |
| Small, EJ | 1 |
| Krzyzanowska, MK | 1 |
| Tannock, IF | 1 |
| Lockwood, G | 1 |
| Knox, J | 1 |
| Moore, M | 1 |
| Bjarnason, GA | 1 |
3 trials available for celecoxib and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.
Topics: Adult; Aged; Carcinoma, Renal Cell; Celecoxib; Cyclooxygenase 2; Dendritic Cells; Dinoprostone; Drug | 2011 |
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carc | 2006 |
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.
Topics: Administration, Oral; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2007 |
3 other studies available for celecoxib and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2017 |
[A case of favorable response after combination treatment with interferon-α and cyclooxygenase-2 inhibitor against metastatic renal cell carcinoma].
Topics: Aged; Carcinoma, Renal Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Huma | 2012 |
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Celecoxib; Cell Line | 2013 |